Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

• Published in: Blood advances 2021-12, Vol.5 (23), p.5258-5268
• Main Authors: Lambert, Juliette, Lambert, Jerome, Thomas, Xavier, Marceau-Renaut, Alice, Micol, Jean-Baptiste, Renneville, Aline, Clappier, Emmanuelle, Hayette, Sandrine, Récher, Christian, Raffoux, Emmanuel, Pigneux, Arnaud, Berthon, Celine, Terré, Christine, Celli-Lebras, Karine, Castaigne, Sylvie, Boissel, Nicolas, Rousselot, Philippe, Preudhomme, Claude, Dombret, Hervé, Duployez, Nicolas
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Clinical Trials and Observations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - therapy; Life Sciences; Middle Aged; Neoplasm, Residual; Prognosis; WT1 Proteins; Young Adult
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2021004322

WT1 overexpression is frequently identified in acute myeloid leukemia (AML) and has been reported to be a potential marker for monitoring measurable residual disease (MRD). We evaluated the use of postinduction WT1 MRD level as a prognostic factor, as well as the interaction between postinduction WT1 MRD response and the effect of allogeneic stem cell transplantation (allo-SCT) in the first complete remission (CR). In the ALFA-0702 trial, patients with AML, aged 18 to 59, had a prospective quantification of WT1 MRD. The occurrence of a WT1 MRD ratio >2.5% in bone marrow or >0.5% in peripheral blood was defined as MRDhigh, and ratios below these thresholds were defined as MRDlow. The prognostic value of MRD after induction chemotherapy was assessed in 314 patients in first CR by comparing the risk of relapse, the relapse-free survival (RFS), and the overall survival (OS). Interaction between MRD response and the allo-SCT effect was evaluated in patients by comparing the influence of allo-SCT on the outcomes of patients with MRDhigh with those with MRDlow. The results showed that patients with MRDhigh after induction had a higher risk of relapse and a shorter RFS and OS. The MRD response remained of strong prognostic value in the subset of 225 patients with intermediate-/unfavorable-risk AML who were eligible for allo-SCT, because patients with MRDhigh had a significantly higher risk of relapse resulting in worse RFS and OS. The effect of allo-SCT was higher in patients with MRDlow than in those with MRDhigh, but not significantly different. The early WT1 MRD response highlights a population of high-risk patients in need of additional therapy. •Postinduction WT1 measurable residual disease is associated with shorter survival and higher risk of relapse in younger patients with AML.•Postinduction WT1 residual disease is an independent prognostic factor in patients eligible for allogeneic stem cell transplantation. [Display omitted]